Buy New
  • List Price: $98.95
  • Save: $7.42 (7%)
Only 2 left in stock (more on the way).
Ships from and sold by
Gift-wrap available.
Sell yours for a Gift Card
We'll buy it for $41.51
Learn More
Trade in now
Have one to sell? Sell on Amazon
Flip to back Flip to front
Listen Playing... Paused   You're listening to a sample of the Audible audio edition.
Learn more
See this image

Design and Analysis of Non-Inferiority Trials (Chapman & Hall/CRC Biostatistics Series) Hardcover – July 12, 2011

ISBN-13: 978-1584888048 ISBN-10: 1584888040 Edition: 1st

Buy New
Price: $91.53
21 New from $86.42 11 Used from $90.79
Rent from Amazon Price New from Used from
"Please retry"
"Please retry"
$86.42 $90.79

Special Offers and Product Promotions

  • Take an Extra 30% Off Any Book: Use promo code HOLIDAY30 at checkout to get an extra 30% off any book for a limited time. Excludes Kindle eBooks and Audible Audiobooks. Restrictions apply. Learn more.

Frequently Bought Together

Design and Analysis of Non-Inferiority Trials (Chapman & Hall/CRC Biostatistics Series) + Preventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide (Practical Guides to Biostatistics and Epidemiology)
Price for both: $124.68

Buy the selected items together

Customers Who Bought This Item Also Bought

Holiday Deals in Books
Holiday Deals in Books
Find deals for every reader in the Holiday Deals in Books store, featuring savings of up to 50% on cookbooks, children's books, literature & fiction, and more.

Product Details

  • Series: Chapman & Hall/CRC Biostatistics Series (Book 43)
  • Hardcover: 454 pages
  • Publisher: Chapman and Hall/CRC; 1 edition (July 12, 2011)
  • Language: English
  • ISBN-10: 1584888040
  • ISBN-13: 978-1584888048
  • Product Dimensions: 6.1 x 1 x 9.2 inches
  • Shipping Weight: 1.9 pounds (View shipping rates and policies)
  • Average Customer Review: 1.0 out of 5 stars  See all reviews (1 customer review)
  • Amazon Best Sellers Rank: #245,501 in Books (See Top 100 in Books)

Editorial Reviews


"… it offers unique perspectives and insights from three renowned experts in clinical trials who work at the U.S. Food and Drug Administration (FDA) and in the pharmaceutical industry. It is refreshing to see FDA and industry perspectives blended thoughtfully, as in this book. … Written clearly and concisely, the book is a pleasure to read. Although there are some technical discussions intended for statisticians, most of the book is readily accessible to medical researchers with little statistical training. We recommend the book to anyone interested in NI trials—statisticians and nonstatisticians alike."
—Zhiwei Zhang and Lei Nie, Journal of the American Statistical Association, March 2014

"It is a pleasure to see a book completely devoted to the challenging arena of non-inferiority trials. … I am very impressed with its depth and breadth, and believe that it will be an important resource for anyone involved in designing non-inferiority trials. The authors weave in many examples, primarily in oncology, as well as a large set of references from the now substantial statistical literature on non-inferiority designs. … This book is a must-have resource for those involved in non-inferiority trials for the pharmaceutical industry, and a must-read for those new to non-inferiority trials. A portion of a special topics course in a biostatistics department could be built around this book, and this exposure would be especially valuable for students considering a career in or around the pharmaceutical industry."
—Erica Brittain, Australian & New Zealand Journal of Statistics, May 2012

"This is the first book which is devoted solely to non-inferiority studies. All three authors have published several papers on that topic over the last years. This comprehensive book covers in more than 400 pages nearly all aspects about non-inferiority trials, and beyond. It is also an excellent source of references about non-inferiority studies. … recommended for anyone working with clinical trials and in particular for those working in late phase drug development. It is an excellent source of concepts and statistical methods relevant for biostatisticians, clinical epidemiologists and students. This book also is a good source for non-inferiority studies for scientists from the clinical field."
—Steffen Witte, Journal of Biopharmaceutical Statistics, 2012

About the Author

Dr. Mark Rothmann earned his Ph. D. in Statistics at the University of Iowa. He taught several years as a professor and has worked at the U. S. Food and Drug Administration. He has done research in many areas involving the design and analysis of clinical trials.

Dr. Brian L. Wiens, received his MS in statistics from Colorado State University and his Ph.D. in statistics from Temple University. He has worked at several pharmaceutical, biotechnology and medical device companies since 1991. He has published research in several areas of design and analysis of clinical trials. Dr. Wiens is a Fellow of the American Statistical Association.

Dr. Ivan S.F. Chan received his M.S. in Statistics from The Chinese University of Hong Kong and his Ph.D. in Biostatistics from University of Minnesota. He has worked at Merck Research Laboratories since 1995 and is currently Senior Director and Franchise Head for vaccines, leading the statistical support for all vaccine clinical research programs at Merck. Dr. Chan has published research in many areas of statistics including exact inference, analysis of non-inferiority trials, and methodologies for clinical trials.

More About the Author

Discover books, learn about writers, read author blogs, and more.

Customer Reviews

1.0 out of 5 stars
5 star
4 star
3 star
2 star
1 star
See the customer review
Share your thoughts with other customers

Most Helpful Customer Reviews

2 of 9 people found the following review helpful By J. P. Miller on June 27, 2012
Format: Kindle Edition Verified Purchase
Note that not all Kindle readers support loading this book - for example it will not load into my Kindle Touch nor can it be read with the Kindle Cloud Reader (e.g. in a browser window). In addition, at least when read on an iPad or a Mac, there are certain symbols which are not rendered (a blank appears) making it difficult to make sense of some formulas.

I cannot believe that even after over 2 years and the issue being brought to the attention of the publishers at convention booths that this has still not been fixed! Not having all symbols rendered correctly is rather critical in mathematical technical books.
2 Comments Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again